Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?

Galectin Therapeutics Ownership Summary

Galectin Therapeutics is owned by 13.84% institutional investors, 29.86% insiders, and 56.30% retail investors. Vanguard group is the largest institutional shareholder, holding 3.56% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.10% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Galectin Therapeutics	13.84%	29.86%	56.30%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	2.29M	3.56%	$9.52M
Blackrock	1.56M	2.52%	$3.53M
Advisor group	1.22M	1.93%	$5.24M
Blackrock funding, inc. /de	796.56K	1.24%	$3.31M
Wealthspire advisors	601.97K	0.94%	$2.50M
Geode capital management	598.07K	0.93%	$2.49M
Marshall wace, llp	554.26K	0.87%	$2.35M
Commonwealth equity services	334.10K	0.52%	$1.39M
Lpl financial	325.26K	0.51%	$1.35M
Goldman sachs group	307.23K	0.48%	$1.28M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Retirement guys formula	184.56K	0.35%	$767.78K
Solutions 4 wealth	25.38K	0.16%	$105.57K
Fortis capital advisors	106.14K	0.07%	$441.54K
Sovran advisors	225.87K	0.06%	$711.50K
Vivaldi capital management lp	172.44K	0.05%	$363.86K
Argyle capital partners	13.38K	0.04%	$56.64K
Gsa capital partners llp	101.97K	0.04%	$424.00K
Geneos wealth management	243.33K	0.02%	$1.01M
Traynor capital management	101.60K	0.02%	$422.66K
Wealthspire advisors	601.97K	0.02%	$2.50M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	1.56M	0.00%	851.14K
Marshall wace, llp	554.26K	0.00%	523.86K
Goldman sachs group	307.23K	0.00%	285.21K
Jane street group	199.34K	0.00%	184.66K
Wealthspire advisors	601.97K	0.02%	122.45K

Top Sellers

Holder	Shares	% Assets	Change
Y-intercept (hong kong)	-	-	-235.19K
Atria wealth solutions	-	-	-186.00K
Soltis investment advisors	-	-	-140.75K
Geneos wealth management	243.33K	0.02%	-116.85K
Cutter & co brokerage	-	-	-115.49K

New Positions

Holder	Shares	% Assets	Change	Value
Barclays	106.40K	0.00%	106.40K	$442.63K
Belpointe asset management	106.14K	0.02%	106.14K	$441.54K
Fortis capital advisors	106.14K	0.07%	106.14K	$441.54K
Virtu financial	38.97K	0.01%	38.97K	$165.00K
Two sigma investments, lp	16.65K	0.00%	16.65K	$70.50K

Sold Out

Holder	Change
Sbi securities	-5.00
Legal & general group	-38.00
Srs capital advisors	-52.00
Sterling capital management	-74.00
Salem investment counselors	-167.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	69	-22.47%	8,887,115	-13.85%	13	5.24%	32	-11.11%	17	-37.04%
Sep 30, 2025	87	-3.33%	10,009,146	-4.34%	15	5.76%	35	-5.41%	26	18.18%
Jun 30, 2025	88	-7.37%	9,965,158	0.59%	15	6.42%	36	24.14%	22	-26.67%
Mar 31, 2025	94	-14.55%	9,893,813	-1.83%	15	5.98%	30	-53.13%	29	222.22%
Dec 31, 2024	110	23.60%	10,078,323	3.40%	16	6.61%	64	64.10%	9	-50.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.35M	2.10%	-
Vanguard US Total Market Shares ETF	1.25M	1.97%	-
Vanguard Institutional Extnd Mkt Idx Tr	563.63K	0.87%	-
Fidelity Extended Market Index	278.69K	0.43%	5.29K
Fidelity Small Cap Index	142.93K	0.23%	-17.81K
Blackrock Extended Mkt Fund CF	127.99K	0.20%	127.99K
iShares Micro-Cap ETF	118.52K	0.18%	55.70K
Extended Equity Market Fund K	109.78K	0.17%	71.00
iShares Russell 2000 Growth ETF	103.67K	0.16%	-
Fidelity Total Market Index	95.49K	0.15%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 06, 2026	ELDRED KARY	-	Buy	$810.00
Jan 02, 2026	LEWIS JOEL	President and CEO	Sell	$77.94K
Jan 05, 2026	LEWIS JOEL	President and CEO	Sell	$108.34K
Jan 06, 2026	LEWIS JOEL	President and CEO	Sell	$134.85K
Jan 02, 2026	CALLICUTT JACK W	Chief Financial Officer	Sell	$58.39K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	9
2025 Q4	2	39
2025 Q3	2	2
2025 Q2	-	-
2025 Q1	-	-

GALT Ownership FAQ

Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 13.84%, followed by 29.86% insiders and 56.30% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 381.47%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Vanguard group (2.29M shares, 3.56%), Blackrock (1.56M shares, 2.52%), and Advisor group (1.22M shares, 1.93%). Together, they hold 8.02% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Retirement guys formula is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.35% of its assets in 184.56K Galectin Therapeutics shares, valued at 767.78K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.10% of its total shares outstanding invested in 1.35M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools